Biological Microchip for Simultaneous Quantitative Immunoassay of Tumor Markers in Human Serum

2009 ◽  
Vol 147 (6) ◽  
pp. 737-741 ◽  
Author(s):  
E. N. Savvateeva ◽  
E. I. Dementieva ◽  
M. V. Tsybulskaya ◽  
T. V. Osipova ◽  
T. P. Ryabykh ◽  
...  
PROTEOMICS ◽  
2016 ◽  
Vol 16 (19) ◽  
pp. 2519-2532 ◽  
Author(s):  
Sarah Strohkamp ◽  
Timo Gemoll ◽  
Jens K. Habermann
Keyword(s):  

2003 ◽  
Vol 1009 (1-2) ◽  
pp. 171-178 ◽  
Author(s):  
N.I. Govorukhina ◽  
A. Keizer-Gunnink ◽  
A.G.J. van der Zee ◽  
S. de Jong ◽  
H.W.A. de Bruijn ◽  
...  

RSC Advances ◽  
2016 ◽  
Vol 6 (98) ◽  
pp. 96202-96202 ◽  
Author(s):  
Shiya Zheng ◽  
Zixue Yang ◽  
Yanping Chen ◽  
Dan Wu ◽  
Shoubing Zhou ◽  
...  

Correction for ‘Simultaneous and combined detection of multiple tumor markers for cancer screening in human serum by an upgraded photonic crystal-encoded suspension array’ by Shiya Zheng et al., RSC Adv., 2016, 6, 92267–92275.


The Analyst ◽  
2016 ◽  
Vol 141 (8) ◽  
pp. 2534-2541 ◽  
Author(s):  
Lu Zhou ◽  
Jun Zhou ◽  
Zhao Feng ◽  
Fuyan Wang ◽  
Shushen Xie ◽  
...  

An immunoassay protocol is described to detect tumor markers in human serum based on a sandwich structure consisting of nano-Si immune probes and SiC@Ag SERS-active immune substrate.


2008 ◽  
Vol 54 (11) ◽  
pp. 1796-1804 ◽  
Author(s):  
Andrew N Hoofnagle ◽  
Jessica O Becker ◽  
Mark H Wener ◽  
Jay W Heinecke

Abstract Background: Quantification of serum tumor markers plays an important role in determining whether patients treated for cancer require further therapy. Whereas large-scale proteomic efforts aim to identify novel tumor markers to facilitate early detection, optimization of methods for quantifying known tumor markers offers another approach to improving management of malignancies. For example, immunoassays used in clinical practice to measure established tumor markers suffer from potential interference from endogenous immunoglobulins and imperfect concordance across platforms—problems that also plague many other immunoassays. To address these important limitations, this study used peptide immunoaffinity enrichment in concert with liquid chromatography–tandem mass spectrometry (LC-MS/MS) to quantify thyroglobulin, a well-characterized tumor marker. Methods: We identified 3 peptides in tryptic digests of thyroglobulin that were detected at low concentrations by tandem mass spectrometry, raised polyclonal antibodies to those peptides, and used the antibodies to extract the 3 corresponding peptides from tryptic digests of human serum. We quantified each endogenous peptide using LC-MS/MS and multiple reaction monitoring with external calibrators. Results: The detection limit for endogenous thyroglobulin in serum was 2.6 μg/L (4 pmol/L). Direct comparison with immunoassay revealed good correlation (r2 = 0.81). Conclusions: Immunoaffinity peptide enrichment–tandem mass spectrometry can detect tryptic peptides of thyroglobulin at picomolar concentrations while also digesting the endogenous immunoglobulins that can potentially interfere with traditional immunoassays. Our observations suggest a general analytical strategy for using immunoaffinity isolation together with tandem mass spectrometry to quantify tumor antigens and other low-abundance proteins in human serum.


Sign in / Sign up

Export Citation Format

Share Document